Portfolio

Collaborative biotech innovation

MTM catalyses the development of next-generation therapeutics for unmet medical needs. We are pushing the boundaries of drug discovery and development, making it faster and more effective.

Lucia Bio

Syk inhibitors for neurodegenerative conditions.
MTM Brisbane Pod

Melio Bio

Leveraging human genetics for better cardiometabolic health.
MTM London Pod

ThirtyFiveBio

Developing a gut epithelial shield for patients with collitis.
MTM Oxford Pod

Pathios Therapeutics

Using human genetics to transform cancer outcomes.
MTM Oxford Pod
Working with MTM supports our focus on developing drugs for patients. Whether it is scientific input from the bioinformatics team, allowing us to interrogate human biology, or financial or company secretarial work that allow us to run an efficient and compliant operation, we are part of the same team.

James Westcott, PhD

CEO, ThirtyFiveBio

Transforming lives through collaborative innovation

Contact us
LinkedIn